Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.00 – $0.00
Volume0
Market cap$4.32B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.32B
Price / earnings
41.63×
Price / book
2.5×
Price / sales
2.36×
EV / sales
3.05×
EV / EBITDA
18.01×
Profitability
Earnings per share
$3.05
Return on assets
3.06%
Return on equity
6.01%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.73×
Current ratio
3.98×
Quick ratio
2.6×
Cash ratio
0.07×
Cash flow
Price / cash flow
24.46×
Price / free cash flow
52.76×
Free cash flow
$81.82M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ITGR, quarterly periods
Line item
Q3 FY2026 Oct 2, 2026
Q2 FY2026 Jul 3, 2026
Q1 FY2026 Apr 3, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 26, 2025
Q2 FY2025 Jun 27, 2025
Q1 FY2025 Mar 28, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$449.66M
$464.11M
$439.58M
$472.06M
$467.69M
$476.49M
$437.39M
$449.5M
Cost of revenue
$348.1M
$351.17M
$329.99M
$347.3M
$341.53M
$347.34M
$317.07M
$332.7M
Gross profit
$101.56M
$112.94M
$109.6M
$124.76M
$126.16M
$129.15M
$120.32M
$116.8M
Selling, general and administrative
$54.15M
$57.7M
$58.71M
$57.21M
$50.45M
$52.92M
$51.16M
$47.47M
Research and development
$13.53M
$11.28M
$16.24M
$10.11M
$10.95M
$14.24M
$14.2M
$10.61M
Total operating expenses
$73.35M
$78.41M
$77.73M
$68.82M
$69.72M
$69.81M
$70.77M
$59.76M
Operating income
$28.21M
$34.53M
$31.87M
$55.94M
$56.44M
$59.34M
$49.55M
$57.03M
Interest expense
-$9.7M
-$10.14M
-$9.73M
-$9.28M
-$9.37M
-$9.75M
-$14.81M
-$13.23M
Income before taxes
$17.51M
$23.29M
$20.35M
$46.81M
$45.99M
$45.6M
-$13M
$39.26M
Income taxes
$2.53M
-$314K
$3.85M
-$1.8M
$6.31M
$8.59M
$9.47M
$6.29M
Net income
$14.98M
$23.61M
$16.51M
$48.61M
$39.68M
$37.01M
-$22.47M
$32.7M
Net income attributable to common shareholders
$14.98M
$23.61M
$16.51M
$48.61M
$39.68M
$37.01M
-$22.47M
$32.7M
EBITDA
$68.24M
$78.5M
$69.65M
$92.94M
$97.8M
$94.28M
$84.79M
$87.64M
Basic earnings per share
$0.44
$0.69
$0.48
$1.39
$1.13
$1.06
-$0.66
$0.97
Diluted earnings per share
$0.43
$0.69
$0.48
$1.31
$1.11
$1.04
-$0.66
$0.90
Recent news
Company coverage with links to the original publishers.
Integer Holdings (ITGR) reported Q3 2026 earnings of $1.34 per share, missing the consensus estimate of $1.65 and down from $1.79 year-ago. Revenue of $449.66 million also fell short of expectations and declined from $467.69 million year-over-year. The company received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions. Despite outperforming the S&P 500 by 61.4% year-to-date, the Medical-Instruments industry remains in the bottom 40% of Zacks-ranked industries.
Thermo Fisher Scientific (TMO) reported quarterly earnings of $6.68 per share, beating consensus estimates of $6.4 and surpassing revenue expectations at $12.14 billion. The company has outperformed the market by 17.3% year-to-date and maintains a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. Integer Holdings (ITGR), another medical device company, is expected to report declining earnings and revenues in its upcoming quarter.
Integer Holdings Corporation (ITGR) is drawing attention from options traders due to high implied volatility in its Dec. 18, 2026 $65 Put options, suggesting market expectations for significant price movement. The company holds a Zacks Rank #3 (Hold) rating in the Medical-Instruments industry, with analyst consensus estimates remaining relatively stable around $1.65-$1.66 per share for the current quarter.
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed transactions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.
In a comparison of two medical instruments stocks, Globus Medical (GMED) emerges as the superior value option over Integer (ITGR). GMED holds a Zacks Rank of #1 (Strong Buy) with improving earnings outlook, while ITGR has a Zacks Rank of #3 (Hold). GMED also demonstrates better valuation metrics with a forward P/E of 15.18 versus ITGR's 20.74, and a PEG ratio of 1.22 compared to ITGR's 2.40, earning GMED a Value grade of B versus ITGR's C.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.